Contents

3 Vaccination questions and concerns

References

  1. Hilton S, Petticrew M, Hunt K. 2006. ‘Combined vaccines are like a sudden onslaught to the body’s immune system’: parental concerns about vaccine ‘overload’ and ‘immune-vulnerability’. Vaccine 24(20): 4321–7.
  2. Leask JA, Chapman S. 1998. An attempt to swindle nature: press anti-immunisation reportage 1993–1997. Australian and New Zealand Journal of Public Health 22(1): 17–26.
  3. Demicheli V, Rivetti A, Debalini MG, et al. 2012. Vaccines for measles, mumps and rubella in children. Cochrane Database of Systematic Reviews. Issue 2, Art. No. CD004407. DOI: 10.1002/14651858.CD004407.pub3 (accessed 27 August 2013).
  4. Institute of Medicine. 2012. Adverse Effects of Vaccines: Evidence and causality Washington DC: The National Academies Press.
  5. Immunize Action Coalition. 2010. Evidence shows vaccines unrelated to autism. Vaccine Concerns: Autism. URL: www.immunize.org/catg.d/p4028.pdf (accessed 31 October 2013).
  6. Offit PA, Hackett CJ. 2003. Addressing parents’ concerns: do vaccines cause allergic or autoimmune diseases? Pediatrics 111(3): 653–9.
  7. Department of Health and Ageing. 2013. Myths and Realities: Responding to arguments against vaccination. URL: www.health.gov.au/internet/immunise/publishing.nsf/content/uci-myths-guideprov (accessed 7 November 2013).
  8. Demicheli V, Jefferson T, Rivetti A, et al. 2005. Vaccines for measles, mumps and rubella in children. Cochrane Database of Systematic Reviews. Issue 4, Art. No. CD004407.
  9. Chao C, Klein NP, Velicer CM, et al. 2012. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. Journal of Internal Medicine 271(2). DOI: 10.1111/j.1365-2796.2011.02467.x (accessed 29 October 2012).
  10. Arnheim-Dahlstroem L, Pasternak B, Svanstroem H, et al. 2013. Autoimmune, neurological and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. British Medical Journal 247:f5906. DOI: 10.1136/bmj.f5906 (accessed 10 December 2016).
  11. Grimaldi-Bensouda L, Guillemot D, Godeau B, et al. 2014. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. Journal of Internal Medicine 275(4): 398–408. DOI: 10.1111/joim.12155 (accessed 10 December 2016).
  12. Langer-Gould A, Qian L, Tartof SY, et al. 2014. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating disease. JAMA Neurology 71(12): 1506–13. DOI: 10.1001/jamaneurol.2014.2633 (accessed 10 December 2016).
  13. Scheller NM, Svanström H, Pasternak B, et al. 2015. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating disease of the central nervous system. Journal of the Americal Medical Association 313(1): 54–61. DOI: 10.1001/jama.2014.16946 (accessed 10 December 2016).
  14. Benarroch EE. 2012. Postural Tachycardia Syndrome: A heterogeneous and multifactorial disorder. Mayo Clinic Proceedings 87(12): 1214–25.
  15. Borucki AN, Grecko CD. 2015. An update on complex regional pain syndromes in children and adolescents. Current Opinion in Pediatrics 27(4): 448–52.
  16. European Medicines Agency. 2015. Pharmacovigilance Risk Assessment Committee (PRAC): Assessment Report: Human papillomavirus (HPV) vaccines (EMA/762033/2015). URL: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/HPV_vaccines_20/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use/WC500197129.pdf (accessed 18 October 2016).
  17. Nguyen M, Ball R, Midthun K, et al. 2012. The Food and Drug Administration’s post-licensure rapid immunization safety monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiology and Drug Safety 21(Suppl 1). DOI: 10.1002/pds.2323 (accessed 26 December 2012).
  18. Kliewer EV, Demers AA, Brisson M, et al. 2010. The Manitoba human papillomavirus vaccine surveillance and evaluation system. [Erratum appears in Health Reports 2010; 21(3): 77]. Health Reports 21(2): 37–42.
  19. Gold MS, McIntyre P. 2010. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. Sexual Health 7(3): 320–4.
  20. World Health Organization. 2015. Global Advisory Committee on Vaccine Safety, 2–3 December 2015. Weekly Epidemiological Record 91(3): 21–31. URL: http://www.who.int/vaccine_safety/committee/reports/wer9103.pdf?ua=1 (accessed 12 October 2016).
  21. World Health Organization. 2016. Meeting of the Strategic Advisory Group of Experts on immunization, April 2016 – conclusions and recommendations. Weekly Epidemiological Record 91(21): 266–84. URL: http://www.who.int/wer/2016/wer9121.pdf?ua=1 (accessed 12 October 2016).
  22. Brotherton JML, Hull BP, Hayen A, et al. 2005. Probability of coincident vaccination in the 24 or 48 hours preceding sudden infant death syndrome death in Australia. Pediatrics 115(6). DOI: 10.1542/peds.2004-2185.
  23. Mitchell EA, Stewart AW, Clements M. 1995. Immunisation and the sudden infant death syndrome: New Zealand Cot Death Study Group. Archives of Disease in Childhood 73(6): 498–501.
  24. Lindgren C, Milerad J, Lagercrantz H. 1997. Sudden infant death and prevalence of whooping cough in the Swedish and Norwegian communities. European Journal of Pediatrics 156(5): 405–9.
  25. Vennemann MMT, Butterfass-Bahloul T, Jorch G, et al. 2007. Sudden infant death syndrome: no increased risk after immunisation. Vaccine 25(2): 336–40.
  26. Vennemann MMT, Hoffgen M, Bajanowski T, et al. 2007. Do immunisations reduce the risk for SIDS? a meta-analysis. Vaccine 25(26): 4875–9.
  27. Offit PA, Quarles J, Gerber MA, et al. 2002. Addressing parents’ concerns: do multiple vaccines overwhelm or weaken the infant’s immune system? Pediatrics 109(1): 124–9.
  28. Dore DD, Turnbull BR, Seeger JD. 2012. Vaccine discontinuation and switching following regulatory interventions in response to rotavirus vaccine contamination with porcine circovirus DNA fragments. Pharmacoepidemiology and Drug Safety 21(4): 415–19.
  29. Clark HF, Offit PA, Parashar UD. 2013. Rotavirus vaccines. In: Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines (6th edition): Elsevier Saunders.
  30. Rizzo P, Matker C, Powers A, et al. 2001. No evidence of HIV and SIV sequences in two separate lots of polio vaccines used in the first US polio vaccine campaign. Virology 287(1): 13–17.
  31. Eickhoff TC, Myers M. 2002. Workshop summary: aluminum in vaccines. Vaccine 20(Suppl 3): 1–4.
  32. Peltola H, Heinonen OP, Valle M, et al. 1994. The elimination of indigenous measles mumps and rubella from Finland by a 12-year, two-dose vaccination program. New England Journal of Medicine 331(21): 1397–1402.
  33. May T, Silverman RD. 2003. ‘Clustering of exemptions’ as a collective action threat to herd immunity. Vaccine 21(11–12): 1048–51.
  34. Hahné S, Macey J, Tipples G. 2005. Rubella outbreak in an unvaccinated religious community in the Netherlands spreads to Canada. Euro Surveillance 10(5): 2704.
  35. Auckland Regional Public Health Service. 2012. Measles. URL: www.arphs.govt.nz/health-information/communicable-disease/measles (accessed 26 October 2013).
  36. Pisacane A, Graziano L, Zona G, et al. 1994. Breast feeding and acute lower respiratory infection. Acta Paediatrica 83(7): 714–18.
  37. Faculty of Homeopathy. 2005. Position Statement: Immunisation. URL: www.facultyofhomeopathy.org/media/position-statements/immunisation (accessed 11 November 2013).